omeprazole and warfarin

omeprazole has been researched along with warfarin in 75 studies

Research

Studies (75)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.67)	18.7374
1990's	10 (13.33)	18.2507
2000's	20 (26.67)	29.6817
2010's	37 (49.33)	24.3611
2020's	6 (8.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W	1
Conradi, R; Lee, PH; Shanmugasundaram, V	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Andersson, T; Blom, H; Idström, JP; Lagerström, PO; Nordgren, A; Svedberg, LE; Unge, P	1
Humphries, TJ	1
Ahmad, S	1
Balmer, K; Boström, H; Eriksson, S; Höglund, P; Paulsen, O; Sutfin, T	1
Gugler, R; Jensen, JC	1
Aomi, S; Fujino, S; Hashimoto, A; Hirai, M; Koyanagi, H; Koyanagi, T; Sakahashi, H; Tokunaga, H	1
Bliesath, H; Duursema, L; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Schall, R; Steinijans, VW	1
Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K	1
Binkley, SN; Ring, BJ; VandenBranden, M; Wrighton, SA	1
Azuma, J; Yamamoto, I	1
Shimada, T; Yamazaki, H	1
Fask, A; Saltiel, E	1
Bertino, JS; Nafziger, AN; Rogers, JF	1
Bell, AR; Crewe, HK; Graham, MJ; Lennard, MS; Moorcraft, CL; Walker, L; Whittaker, EF	1
Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y	1
Chan, E; Zhou, Q	1
Fuhr, U; Kober, S; Mutschler, E; Spahn-Langguth, H; Zaigler, M	1
Chan, E; Zhou, Q; Zhou, S	1
Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y	1
Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH	1
Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF	1
Haas, SJ	1
Sugawara, K; Sugimoto, K; Tateishi, T; Uno, T	1
Boulenc, X; Brian, W; Donazzolo, Y; Poitiers, F; Santoni, A; Turpault, S; Van Horn, R	1
Bali, M; Gill, NS; Muthuraman, A; Sharma, PD; Sood, S	1
Bertilsson, L; Eliasson, E; Masquelier, M; Ostervall, J; Otto, S; Rosenborg, S; Stenberg, M; Yue, QY	1
Miller, GP	1
Cho, SH; Hong, KS; Jung, JW; Kang, HR; Kim, TE; Kwon, JW; Lee, SH; Yu, KS	1
Gammack, JK; Messinger-Rapport, BJ; Morley, JE; Thomas, DR	1
Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H	1
Kailajärvi, M; Lammintausta, R; Lehtinen, T; Pelkonen, O; Scheinin, M; Stjernschantz, C; Tapanainen, P; Turpeinen, M; Uusitalo, J; Vuorinen, J	1
Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM	1
Chong, E; Kalia, V; Willsie, S; Winkle, P	1
Matsumoto, Y; Matsushita, A; Murayama, N; Shukuya, M; Uno, Y; Yamazaki, H	1
Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K	1
Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS	1
Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y	1
Murayama, N; Shida, S; Shimizu, M; Uno, Y; Utoh, M; Yamazaki, H	1
Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H	1
Inoue, T; Kawano, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H	1
Shida, S; Yamazaki, H	1
Kawano, M; Mitsui, M; Sasaki, E; Shimizu, M; Suemizu, H; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H	1
Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA	1
Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN	1
Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H	1
Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A	1
Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H	1
Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA	1
Inoue, T; Kusama, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H	1
Gong, Z; Huang, J; Li, Y; Liu, C; Liu, T; Lu, Y; Pan, J; Sun, J; Wang, Y; Zheng, J; Zheng, L	1
Bailey-Smith, C; Bodrug, I; Cheng, A; Glasgow, XS; Hussain, A; Iwamoto, M; Khalilieh, S; Levine, V; Martinho, M; Mekokishvili, L; Montgomery, D; Shaw, PM	1
Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y	1
Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K	1
Chung, JY; Hatley, O; Kim, Y; Lee, H; Lee, HA; Rhee, SJ; Yi, S; Yoon, S; Yu, KS	1
Enejosa, JV; Feng, T; Fisniku, O; Mohamed, MF; Othman, AA	1
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC	1
Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y	1
Chen, Y; Miao, X; Wang, L; Zhou, H; Zhou, W	1
Newman, EM; Rowland, A	1
Fan, Y; Feng, S; Fu, M; Gu, F; Huang, J; Lin, H; Lu, Z; Luo, L; Shen, K; Wu, B	1

Reviews

6 review(s) available for omeprazole and warfarin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive diseases and sciences, 1991, Volume: 36, Issue:12 Topics: Aminopyrine; Animals; Antipyrine; Cytochrome P-450 Enzyme System; Diazepam; Drug Interactions; Humans; Omeprazole; Phenytoin; Propranolol; Theophylline; Warfarin	1991
Lack of pantoprazole drug interactions in man. International journal of clinical pharmacology and therapeutics, 1994, Volume: 32, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin	1994
[Individualization of drug therapy and pharmacogenetics]. Nihon rinsho. Japanese journal of clinical medicine, 1998, Volume: 56, Issue:3 Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Azathioprine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Immunosuppressive Agents; Methyltransferases; Mixed Function Oxygenases; Mutation; Omeprazole; Polymorphism, Genetic; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Warfarin	1998
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. The American journal of medicine, 2002, Dec-15, Volume: 113, Issue:9 Topics: Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Codeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Diazepam; Genotype; Glipizide; Humans; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Phenotype; Phenytoin; Warfarin	2002
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. International journal of molecular sciences, 2022, Oct-04, Volume: 23, Issue:19 Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin	2022

Trials

21 trial(s) available for omeprazole and warfarin

Article	Year
A study of the interaction of omeprazole and warfarin in anticoagulated patients. British journal of clinical pharmacology, 1992, Volume: 34, Issue:6 Topics: Adult; Aged; Blood Coagulation Factors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Humans; Middle Aged; Omeprazole; Warfarin; Whole Blood Coagulation Time	1992
Stereoselective interaction of omeprazole with warfarin in healthy men. Therapeutic drug monitoring, 1989, Volume: 11, Issue:2 Topics: Adult; Blood Coagulation; Double-Blind Method; Drug Interactions; Humans; Male; Omeprazole; Random Allocation; Stereoisomerism; Warfarin	1989
Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. British journal of clinical pharmacology, 1995, Volume: 39, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Blood Coagulation; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Warfarin	1995
Lack of pantoprazole drug interactions in man. International journal of clinical pharmacology and therapeutics, 1994, Volume: 32, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin	1994
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clinical pharmacology and therapeutics, 2003, Volume: 74, Issue:5 Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase	2003
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. Journal of clinical pharmacology, 2005, Volume: 45, Issue:12 Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase	2005
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. Journal of clinical pharmacology, 2006, Volume: 46, Issue:5 Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; CCR5 Receptor Antagonists; Dextromethorphan; Diketopiperazines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Omeprazole; Piperazines; Spiro Compounds; Warfarin	2006
The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Therapeutic drug monitoring, 2008, Volume: 30, Issue:3 Topics: Adult; Alleles; Anticoagulants; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Interactions; Female; Genotype; Humans; Male; Mixed Function Oxygenases; Omeprazole; Phenotype; Prothrombin Time; Proton Pump Inhibitors; Stereoisomerism; Warfarin	2008
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. British journal of clinical pharmacology, 2009, Volume: 68, Issue:6 Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Warfarin; Young Adult	2009
Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anticoagulants; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Female; Glucosamine; Humans; Losartan; Male; Middle Aged; Noscapine; Omeprazole; Phenotype; Warfarin; Young Adult	2010
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. Journal of clinical pharmacology, 2014, Volume: 54, Issue:4 Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult	2014
Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Journal of nephrology, 2014, Volume: 27, Issue:6 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Area Under Curve; Cardiotonic Agents; Chelating Agents; Digoxin; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Ferric Compounds; Furosemide; Half-Life; Healthy Volunteers; Humans; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Sucrose; Warfarin; Young Adult	2014
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans. Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:6 Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult	2015
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. Journal of clinical pharmacology, 2015, Volume: 55, Issue:12 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Warfarin; Young Adult	2015
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clinical pharmacokinetics, 2017, Volume: 56, Issue:10 Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult	2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. British journal of clinical pharmacology, 2018, Volume: 84, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Caffeine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Tandem Mass Spectrometry; Warfarin	2018
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role? European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:2 Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin	2018
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. British journal of clinical pharmacology, 2018, Volume: 84, Issue:10 Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Injections, Subcutaneous; Interleukin-23 Subunit p19; Male; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Treatment Outcome; Warfarin; Young Adult	2018
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. Clinical pharmacokinetics, 2019, Volume: 58, Issue:6 Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Midazolam; Omeprazole; Psoriasis; Severity of Illness Index; Substrate Specificity; Warfarin	2019
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail. Journal of clinical pharmacology, 2020, Volume: 60, Issue:1 Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Midazolam; Middle Aged; Omeprazole; Phenotype; Vitamin K; Warfarin	2020
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. Clinical and translational science, 2020, Volume: 13, Issue:6 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Warfarin; Young Adult	2020

Other Studies

49 other study(ies) available for omeprazole and warfarin

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. European journal of medicinal chemistry, 2009, Volume: 44, Issue:11 Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution	2009
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay. Bioorganic & medicinal chemistry letters, 2010, Jan-01, Volume: 20, Issue:1 Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption	2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Omeprazole-warfarin interaction. Southern medical journal, 1991, Volume: 84, Issue:5 Topics: Drug Interactions; Humans; Male; Middle Aged; Omeprazole; Prothrombin Time; Warfarin	1991
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology, 1985, Volume: 89, Issue:6 Topics: Adult; Benzimidazoles; Coumarins; Diazepam; Drug Interactions; Humans; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Nordazepam; Omeprazole; Oxidation-Reduction; Phenytoin	1985
[A case report of prosthetic valve replacement for malfunction of the Hancock valve in mitral position associated with recurrent peptic ulcer and renal dysfunction]. Kyobu geka. The Japanese journal of thoracic surgery, 1995, Volume: 48, Issue:10 Topics: Female; Heart Valve Prosthesis; Humans; Kidney Diseases; Middle Aged; Mitral Valve; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prosthesis Failure; Recurrence; Reoperation; Warfarin	1995
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics, 1996, Volume: 6, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Kinetics; Liver; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Proton-Translocating ATPases; Rabbits; Rabeprazole; Recombinant Proteins; Sulfaphenazole; Theophylline	1996
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica; the fate of foreign compounds in biological systems, 1999, Volume: 29, Issue:3 Topics: Arachidonic Acid; Aryl Hydrocarbon Hydroxylases; Cholecalciferol; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Ethanolamines; Humans; Isoenzymes; Lauric Acids; Microsomes, Liver; Mixed Function Oxygenases; Nifedipine; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Paclitaxel; Prostaglandins; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline; Tretinoin; Warfarin; Xenobiotics	1999
Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies. Clinical therapeutics, 1999, Volume: 21, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diazepam; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pharmacies; Prevalence; Proton Pump Inhibitors; Retrospective Studies; Theophylline; Warfarin	1999
mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica; the fate of foreign compounds in biological systems, 2003, Volume: 33, Issue:3 Topics: Algorithms; Animals; Cytochrome P-450 Enzyme System; Dextromethorphan; Dogs; Female; Humans; Isoenzymes; Kinetics; Liver; Male; Mephenytoin; Microsomes, Liver; Omeprazole; Protein Biosynthesis; RNA, Messenger; Warfarin	2003
Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2003, Volume: 20, Issue:4-5 Topics: Algorithms; Animals; Anti-Ulcer Agents; Anticoagulants; Biotransformation; Drug Interactions; Hydroxylation; In Vitro Techniques; Indicators and Reagents; Male; Microsomes, Liver; Omeprazole; Oxidation-Reduction; Protein Binding; Rats; Rats, Sprague-Dawley; Stereoisomerism; Warfarin	2003
Rate-limiting biotransformation of triamterene is mediated by CYP1A2. International journal of clinical pharmacology and therapeutics, 2005, Volume: 43, Issue:7 Topics: Caffeine; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Humans; Hydroxylation; Ketoconazole; Kinetics; Microsomes, Liver; Omeprazole; Quinidine; Substrate Specificity; Sulfuric Acid Esters; Theophylline; Triamterene	2005
Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Algorithms; Anti-Ulcer Agents; Anticoagulants; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; DNA, Complementary; Humans; Hydroxylation; In Vitro Techniques; Isoenzymes; Microsomes, Liver; Omeprazole; Stereoisomerism; Warfarin	2005
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin	2006
Is this medicine really involved in a drug interaction? Southern medical journal, 2007, Volume: 100, Issue:4 Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digoxin; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Risk Factors; Warfarin	2007
Role of 7,8-dimethoxycoumarin in anti-secretary and anti-inflammatory action on pyloric ligation-induced gastritis in rats. Journal of Asian natural products research, 2010, Volume: 12, Issue:7 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Citrus; Coumarins; Gastritis; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Omeprazole; Pylorus; Rats; Rats, Wistar	2010
Warfarin therapy: how the less interesting half just got interesting. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:12 Topics: Acetaminophen; Anticoagulants; Azithromycin; Cimetidine; Cytochrome P-450 Enzyme System; Drug Interactions; Gefitinib; Humans; Omeprazole; Quinazolines; Stereoisomerism; Substrate Specificity; Warfarin	2010
The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. The Tohoku journal of experimental medicine, 2011, Volume: 224, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Anticoagulants; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Prothrombin Time; Proton Pump Inhibitors; Pyrimidinones; Tetrahydroisoquinolines; Thrombosis; Warfarin	2011
Clinical update on nursing home medicine: 2011. Journal of the American Medical Directors Association, 2011, Volume: 12, Issue:9 Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delirium; Diabetes Complications; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Geriatric Nursing; Humans; Male; Nursing Homes; Omeprazole; Osteoporosis; Peptic Ulcer; Platelet Aggregation Inhibitors; Pneumonia, Bacterial; Polypharmacy; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Warfarin; Weight Loss	2011
Warfarin. BMJ (Clinical research ed.), 2011, Nov-02, Volume: 343 Topics: Anti-Infective Agents; Anti-Ulcer Agents; Anticoagulants; Drug Interactions; Educational Measurement; Humans; Metronidazole; Omeprazole; Warfarin	2011
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. The Journal of toxicological sciences, 2012, Volume: 37, Issue:6 Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin	2012
Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. International journal of molecular sciences, 2013, Jul-05, Volume: 14, Issue:7 Topics: Aged; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Area Under Curve; Bupropion; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Hepatocytes; Humans; Microsomes, Liver; Middle Aged; Omeprazole; Tamoxifen; Warfarin	2013
CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. Biochemical pharmacology, 2014, Sep-15, Volume: 91, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Flurbiprofen; Gene Expression Regulation, Enzymologic; Macaca fascicularis; Macaca mulatta; Microsomes, Liver; Models, Molecular; Omeprazole; Polymorphism, Genetic; Protein Conformation; Proton Pump Inhibitors; Warfarin	2014
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica; the fate of foreign compounds in biological systems, 2015, Volume: 45, Issue:4 Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin	2015
Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica; the fate of foreign compounds in biological systems, 2015, Volume: 45, Issue:10 Topics: Administration, Intravenous; Administration, Oral; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Biological; Omeprazole; Pharmacokinetics; Warfarin	2015
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin	2016
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:10 Topics: Amino Acid Sequence; Animals; Callithrix; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Humans; Macaca fascicularis; Male; Microsomes, Liver; Molecular Sequence Data; Omeprazole; Phylogeny; Species Specificity; Substrate Specificity; Tolbutamide; Warfarin	2015
Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:9 Topics: Animals; Cytochrome P-450 Enzyme System; Dogs; Humans; Metoprolol; Midazolam; Models, Biological; Omeprazole; Swine; Swine, Miniature; Warfarin	2016
Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:12 Topics: Animals; Caffeine; Chimera; Cytochrome P-450 Enzyme System; Dogs; Humans; Macaca fascicularis; Mice; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations; Pharmacokinetics; Swine; Swine, Miniature; Warfarin	2016
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR. PloS one, 2016, Volume: 11, Issue:7 Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin	2016
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:7 Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin	2018
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Advances in therapy, 2017, Volume: 34, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin	2017
Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:10 Topics: Administration, Oral; Animals; Area Under Curve; Callithrix; Cytochrome P-450 CYP2C19; Genetic Association Studies; Liver; Models, Biological; Omeprazole; Polymorphism, Genetic; Warfarin	2018
Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches. Molecules (Basel, Switzerland), 2017, Nov-20, Volume: 22, Issue:11 Topics: Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P450 Family 2; Drugs, Chinese Herbal; Enzyme Activation; Herb-Drug Interactions; Isoenzymes; Midazolam; Omeprazole; Rats; Steroid 16-alpha-Hydroxylase; Tolbutamide; Warfarin	2017
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. The AAPS journal, 2019, 03-18, Volume: 21, Issue:3 Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin	2019
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharmaceutics & drug disposition, 2019, Volume: 40, Issue:3-4 Topics: Adult; Asian People; Computer Simulation; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Lorazepam; Male; Metoprolol; Midazolam; Middle Aged; Models, Biological; Omeprazole; Rosuvastatin Calcium; Software; Warfarin; Young Adult	2019
The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population. Current molecular pharmacology, 2020, Volume: 13, Issue:3 Topics: Alleles; Amino Acid Sequence; Asian People; Catalytic Domain; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Fluoxetine; Humans; Ketoconazole; Kinetics; Loratadine; Models, Molecular; Molecular Docking Simulation; Mutagenesis, Site-Directed; Nitriles; Omeprazole; Polymorphism, Genetic; Protein Conformation; Protein Isoforms; Recombinant Proteins; Sertraline; Substrate Specificity	2020
Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases. Clinical and translational science, 2022, Volume: 15, Issue:2 Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Warfarin	2022
Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis. British journal of clinical pharmacology, 2023, Volume: 89, Issue:12 Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Warfarin	2023